Gilead Sciences, Inc.

NASDAQ:GILD

Drug Manufacturers - General

Healthcare
$168.98 -2.14%

-$2.69 today

Market cap
$209.59B
Beta
0.33
P/E (TTM)
16.5
EPS (TTM)
$7.42
Dividend yield
2.62%
52W Low $104.46High $157.29

Volume 4.82M

Average 6.78M

GILD Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Gilead Sciences, Inc.NASDAQ: GILD

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation turns negative

Q2 FY2026 stock-based compensation was -$218M, compared with $225M a year earlier. Trailing-twelve-month stock-based compensation was $460M. Over 3 fiscal years it compounded at +11.6% a year.

Context

  • Stock-based compensation amounted to 3.0% of revenue in FY2025, up 0.1 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near -$218M or moves back toward the trailing-twelve-month quarterly average of $115M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$218M-200.0% QoQ
Last fiscal yearDec 2025
$894M+7.1% YoY
LTMJun 2026
$460M-47.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-196.9%——
1 year+7.1%——
3-year CAGR+11.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
894M USD
Year-over-year change
+7.1%
4-year CAGR
+8.9%

Stock-Based Compensation vs competitors

How GILD compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -47.2% is the lowest of 8, against a peer median of +7.6%.
  • Stock-based compensation amounts to 1.5% of revenue for GILD, versus a peer median of 1.0%.
GILD Competitors
Stock-Based Compensation for GILD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$1.42B USD+11.0%+6.0%1.4%
ABBVAbbVie Inc.LTM Jun 2026$976M USD+4.5%+12.5%1.5%
PFEPfizer Inc.LTM Jun 2026$947M USD+14.9%-2.9%1.5%
MRKMerck & Co., Inc.LTM Jun 2026$892M USD+12.5%—1.3%
LLYEli Lilly and CompanyLTM Jun 2026$649.2M USD+5.8%+19.0%0.8%
NVSNovartis AGLTM Jun 2026$571M USD-45.9%—1.0%
GILDGilead Sciences, Inc.LTM Jun 2026$460M USD-47.2%+11.6%1.5%
SNYSanofiLTM Jun 2026€184M EUR+7.6%—0.4%
AZNAstraZeneca PLCLTM Sep 2026$0 USD——0.0%
GSKGSK plcLTM Jun 2026£0 GBP——0.0%
Peer median (excluding GILD) —+7.6%+9.2%1.0%

Competitors are the stored peer set for GILD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income6.2B4.59B5.67B480M8.51B
Depreciation & Amortization2.05B2.1B2.69B2.77B2.76B
Deferred Income Tax(116M)(1.55B)(962M)(1.84B)160M
Stock-Based Compensation635M644M766M835M894M
Change in Working Capital489M(1.76B)(2.3B)(880M)(3.95B)
Accounts Receivables313M(406M)157M139M(367M)
Inventory11M(310M)(842M)(426M)(1.04B)
Accounts Payables(118M)226M(347M)290M(132M)
Other Working Capital283M(1.27B)(1.27B)(883M)(2.41B)
Other Non-Cash Items2.13B5.05B2.15B9.47B1.64B
Operating Cash Flow11.38B9.07B8.01B10.83B10.02B
Capital Expenditures(579M)(728M)(585M)(523M)(563M)
Acquisitions (Net)(1.58B)(1.8B)(1.15B)(4.84B)(1.07B)
Purchases of Investments(3.9B)(1.94B)(2.37B)(736M)(4.07B)
Sales of Investments2.91B2B1.84B2.59B909M
Other Investing Activities19M(1M)058M3M
Investing Cash Flow(3.13B)(2.47B)(2.27B)(3.45B)(4.79B)
Debt Repayment(4.75B)(1.5B)(270M)1.49B(1.79B)
Common Stock Issued169M309M232M422M408M
Common Stock Repurchased(546M)(1.4B)(1B)(1.15B)(1.92B)
Dividends Paid(3.61B)(3.71B)(3.81B)(3.92B)(4B)
Other Financing Activities(145M)(173M)(278M)(281M)(440M)
Financing Cash Flow(8.88B)(6.47B)(5.13B)(3.43B)(7.75B)
Effect of Forex Changes(35M)(63M)57M(40M)92M
Net Change in Cash(659M)74M673M3.91B(2.43B)
Free Cash Flow10.81B8.34B7.42B10.31B9.46B

Gilead Sciences, Inc.

NASDAQ:GILD

Intrinsic Alpha fair value

Locked

Current Price

$168.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.